Dragomir B. Krastev
London, ENG SW36JB, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.
Journal: Nature communications
Published: December 04, 2024
Nucleophagy removes cytotoxic trapped PARP1.
Journal: Nature cell biology
Published: September 10, 2024
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
Journal: Oncogene
Published: June 17, 2024
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.
Journal: Nature communications
Published: March 18, 2024
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Journal: Molecular oncology
Published: May 11, 2023
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Journal: Oncogene
Published: March 03, 2023
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Journal: Cell reports
Published: September 02, 2022
Opinion: PARP inhibitors in cancer-what do we still need to know?
Journal: Open biology
Published: July 27, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
Journal: Cancer research
Published: December 21, 2021
Loss of USP28 and SPINT2 expression promotes cancer cell survival after whole genome doubling.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: November 25, 2021
Last Updated: 09/26/2026